Swetha Durai

Swetha Durai

Auto-generated profile, based on publicly available information

Swetha Durai

Independent Research Consultant, Tamil Nadu, India

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 February 2026 in International Journal Of Community Medicine And Public Health
Verified
Journal Article
Open access
PDF file
CSChandru Sivamani
Chandru Sivamani
KOKavipriya Outtamane
Kavipriya Outtamane
SASona Priyanka Auroprem
Sona Priyanka Auroprem
SDSwetha Durai
Swetha Durai
KSKavya S.
Kavya S.
India’s National Oral Health Programme (NOHP) was launched in 2014 to strengthen oral health services, however, a consolidated evaluation of its implementation and progress remains limited. Therefore, we aimed to synthesize evidence on India’s oral disease burden and oral health system progress (NOHP) from 2014 to 2025. A comprehensive search was conducted in PubMed, Embase, Google Scholar, and government websites (August-October 2025). We included all study designs, reports and programme documents (2014-25), excluding non-oral health and non-English/non-full text articles. Data extraction covered major dental conditions, and programme domains were mapped using WHO health-system building blocks. Findings were narratively summarised, NOHP’S funding mapped using QGIS 3.28, and study quality appraised using SANRA checklist. Dental caries prevalence ranged from 19.6% to 94% (mean DMFT/DMFT: 0.4-2.8). Gingivitis affected 46.6% of the population and periodontitis was 51% (≥15 years). Partial edentulism ranged 13.4-100% and the complete edentulism was 5.3-90.5%, with national estimates of 61.9% and 7.2% (≥45 years), respectively. Orofacial clefts occurred at a rate of 0.9 per 1,000 births, with 50-60% of cases being cleft lip and palate. India reported 143,759 new oral cancer cases in 2022 (ASR: 9.9/100,000). Programme improvements included PHC-level dental units, tobacco cessation centres, mobile-dental vans, screening collaborations (NTCP, NP-NCD, RBSK), school dental programmes and dental amalgam phase-down. Despite 3.7 lakh dentists, rural availability remains low (1:25000). Two Centres of Excellence and three National Resource Centres were established, alongside the national oral health policy draft. India has strengthened oral health services (OHS) under NOHP, yet gaps persist in coverage, funding, oral health information management system (OHIMS) and workforce distribution. Stronger primary-care integration, expanding preventive services and unified OHIMS are essential for equitable OHS.

30 September 2026 in International Journal Of Community Medicine And Public Health
Verified
Journal Article
Open access
PDF file
SASona Priyanka Auroprem
Sona Priyanka Auroprem
RRRoopa Sri Ravichandran
Roopa Sri Ravichandran
SDSwetha Durai
Swetha Durai
NANandhan Auro
Nandhan Auro
SMSabeetha Lakshmi Madhavan
Sabeetha Lakshmi Madhavan
HSHariharan Selvam
Hariharan Selvam
People with disabilities (PWDs) experience a disproportionately high burden of multimorbidity and long-term medication use, increasing their risk of polypharmacy and medication-related harm. This narrative review synthesised evidence on the prevalence and patterns of polypharmacy, mechanisms contributing to medication-related harm, deprescribing practices, medication optimisation strategies, and research gaps among individuals with disabilities. In accordance with the Scale for the Assessment of Narrative Review Articles (SANRA) guidelines, searches of PubMed, Scopus, Google Scholar, and grey literature were conducted to identify studies published in English from January 2010 to May 2026. Eligible studies included individuals with recognised disabilities and reported outcomes related to polypharmacy, inappropriate prescribing, adverse drug events, medication-related harm, pharmacokinetic changes, or deprescribing. Due to heterogeneity in populations, disability types, and reported outcomes, findings were synthesised narratively. Evidence indicated a high prevalence of polypharmacy among individuals with intellectual and developmental disabilities, spinal cord injury, cerebral palsy, and multiple sclerosis, with substantial medication burdens occurring earlier than in the general population. Psychotropic polypharmacy was particularly prevalent among individuals with intellectual and developmental disabilities. Medication-related harm was influenced by polypharmacy, disability-specific pharmacokinetic alterations, communication barriers, medication errors, fragmented healthcare delivery, and limited continuity of care. Multidisciplinary medication reviews, structured deprescribing, and person-centred medication optimisation showed promise, although evidence remains limited, particularly in low- and middle-income countries. Strengthening medication assessment, deprescribing, accessible communication, caregiver support, and evidence-based prescribing is essential to improve medication safety and promote equitable, person-centred care for people with disabilities.